The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Restoration of tumor suppression in vivo by systemic delivery of chemically-modified PTEN mRNA nanoparticles.
 
Mohammad Ariful Islam
Patents, Royalties, Other Intellectual Property - Brigham and Women's Hospital
 
Yingjie Xu
No Relationships to Disclose
 
Harshal Zope
Employment - Waveguide Corporation
Stock and Other Ownership Interests - Waveguide Corporation
Patents, Royalties, Other Intellectual Property - Leidein University (Inst)
 
Wuji Cao
No Relationships to Disclose
 
Morteza Mahmoudi
Patents, Royalties, Other Intellectual Property - Brigham and Women's Hospital; Philip Universitat Marburg
 
Robert Langer
Leadership - Moderna Therapeutics; Selecta Biosciences; Tarveda Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics; Selecta Biosciences; Tarveda Therapeutics
Consulting or Advisory Role - Moderna Therapeutics; Selecta Biosciences; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Moderna Therapeutics; Selecta Biosciences; Tarveda Therapeutics
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Metamark Genetics; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Cristal Therapeutics; Druggablity Technologies; Endocyte; Genentech/Roche; GTx; Ipsen; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Pfizer; Progenity; Sanofi; Sotio; Tarveda Therapeutics; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Sanofi
 
Jinjun Shi
Patents, Royalties, Other Intellectual Property - Brigham and Women's Hospital
 
Bruce R. Zetter
Stock and Other Ownership Interests - Celgene (I)
Consulting or Advisory Role - Metastat; Serra Therapeutics; SynDevRx; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Boston Children's Hospital
 
Omid C. Farokhzad
Leadership - Selecta Biosciences; Tarveda Therapeutics
Stock and Other Ownership Interests - Selecta Biosciences; Tarveda Therapeutics
Consulting or Advisory Role - Selecta Biosciences; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Selecta Biosciences; Tarveda Therapeutics